Dr. Kamdar Shares Liso-Cel Data From TRANSCEND-MCL Study

Manali Kamdar, MD, of the University of Colorado Cancer Center, shares data on lisocabtagene maraleucel (liso-cel) in patients with relapsed or refractory mantle cell lymphoma (MCL) presented at the 2024 American Society of Clinical Oncology Annual Meeting.

In the subgroup analysis of the TRANSCEND NHL 001 trial, liso-cel resulted in durable complete responses at 72.0% with low incidence of cytokine release syndrome, Dr. Kamdar explained. For the overall population, the duration of response (DOR) was 15.7 months, the progression-free survival (PFS) was 15.3 months, and the overall survival (OS) was 18.2 months.

The study compared treatment response based on prior systemic lines of therapy and prior Bruton’s tyrosine kinase (BTK) inhibition.

“When you divvy them up based on number of prior lines of systemic therapy, patients who had two or three to four prior lines of treatment had a very comparable DOR, PFS, and OS,” Dr. Kamdar explained. “For patients who had a median of five or more prior lines of treatment, the median duration of response was lower at 6.7 months, median PFS at 7.4 months, and median OS at 13.5 months.”

She also noted that safety across subgroups was also consistent with the overall population, but with a numerically higher incidence of cytopenias in those who had received five or more prior lines of treatment.

“The better efficacy outcomes, as well as the excellent safety profile observed in patients with relapsed or refractory MCL who received less than five prior lines of treatment, and those with disease not refractory to prior BTK inhibition, support the use of liso-cel in earlier lines of treatment,” Dr. Kamdar concluded.